论文部分内容阅读
作者根据WHO新的肿瘤疗效评估法(全效—肿瘤完全消失4周以上;部份有效—肿瘤缩小50％或更多至少4周;无效—肿瘤缩小50％以下或增大25％以下,无新的肿瘤灶;恶化—肿瘤增大25％以上,出现新肿瘤灶)对543例喉癌(男510,女33)的放疗效果进行分析。肿瘤部位:喉前庭175例,喉中份111例,中上份183例,中下份31例,全喉43例。分期:T_129例,T_2130例,T_3333例,T_451例。颈淋巴结转移:N_0492例,N_129例,N_215例,N_37例。生长性质:外生性生长256例,内生性生长121例,混合性生长166例。分化程度:分化良好伴角化者259例,分化良好非角化者179例,低
The authors according to the WHO new tumor efficacy evaluation method (full effect - the tumor completely disappeared for more than 4 weeks; partially effective - the tumor shrinks by 50% or more for at least 4 weeks; invalid - the tumor shrinks by 50% or less, increase by 25% or less, no New tumor foci; deterioration - tumors increased by more than 25%, new tumor foci appeared) Analysis of radiotherapy effects of 543 laryngeal cancers (male 510, female 33). Tumor sites: 175 cases of laryngeal vestibule, 111 cases of middle larynx, 183 cases of middle and upper parts, 31 cases of middle and lower parts, and 43 cases of total laryngectomy. Stages: T_129 cases, T_2130 cases, T_3333 cases, T_451 cases. Cervical lymph node metastasis: N_0492 cases, N_129 cases, N_215 cases, N_37 cases. Growth properties: Exogenous growth in 256 cases, endogenous growth in 121 cases, mixed growth in 166 cases. Degree of differentiation: 259 cases with well-differentiated hyperkeratosis, 179 cases with well-differentiated non-keratinized, low